COHANCE444.00

Cohance Lifesciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹16,987 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,051.41,197.62,268.62,690.8
Other Income61.958.634.146.3
Total Income1,113.31,256.12,302.62,737.2
Expenses
+ Cost of Materials Consumed265.9222.7705.4864.1
+ Changes in Inventories49.282.6-42.8-81.2
+ Employee Benefit Expense135.9249.6507.7640.7
+ Finance Costs7.512.437.244.0
+ Depreciation & Amortisation54.677.5187.3236.9
+ Other Expenses194.6267.5671.2839.1
Total Expenses707.6912.22,066.12,543.5
EBITDA405.8375.2427.0428.2
EBIT351.2297.7239.7191.3
Profit
PBT before Exceptional Items405.7343.9236.5193.6
+ Exceptional Items0.00.0-29.5-29.5
Pretax Income405.7343.9207.0164.2
+ Current Tax98.893.379.982.1
+ Deferred Tax6.6-14.2-23.0-22.8
Tax Expense105.479.256.959.2
Net Income300.3264.8150.1104.9
+ Net Income — Continuing Ops300.3264.8150.1104.9
+ Other Comprehensive Income13.213.199.0104.8
Total Comprehensive Income313.5277.9249.2209.8
Net Income to Common0.0267.9179.2155.1
Minority Interest0.0-3.1-29.1-50.2
Per Share
Basic EPS11.8010.524.694.06
Diluted EPS11.8010.454.684.01
Other Comprehensive Income — detail
+ Other Comprehensive Income13.199.0104.8
+ Items NOT to be Reclassified to P&L0.18.996.897.0
+ Tax on Items NOT to be Reclassified2.626.626.6
+ Tax on Items NOT to be Reclassified — alt tag-0.1
+ Items to be Reclassified to P&L13.06.826.334.0
+ Tax on Items to be Reclassified0.0-2.5-0.5
Comprehensive Income — Owners of Parent0.0280.4270.7252.4
Comprehensive Income — Non-controlling Interests0.0-2.5-21.5-42.6
Per Share — as-filed variants
Basic EPS — Continuing Operations11.8010.524.694.06
Diluted EPS — Continuing Operations11.8010.454.684.01
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit736.3892.31,605.91,907.9
Gross Margin %70.0474.5170.7970.90
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)405.7343.9236.5193.6
− Exceptional Items (reconciliation)0.00.0-29.5-29.5
Net Income Adj (tax-effected)300.3264.8171.5123.8
EPS Adj11.8010.525.364.79
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital25.525.538.338.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.